Anteris Technologies Global (NASDAQ:AVR) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Anteris Technologies Global (NASDAQ:AVR) announced its earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09), FiscalAI reports. The firm had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative net margin of 5,148.78% and a negative return on equity of 124.76%. During the same period last year, the company earned ($0.58) earnings per share.

Anteris Technologies Global Price Performance

Shares of NASDAQ:AVR traded down $0.48 on Wednesday, reaching $8.69. The company’s stock had a trading volume of 270,171 shares, compared to its average volume of 1,173,310. The stock’s 50-day moving average is $9.15 and its two-hundred day moving average is $7.33. Anteris Technologies Global has a 52-week low of $3.30 and a 52-week high of $11.06. The stock has a market capitalization of $846.27 million, a P/E ratio of -3.90 and a beta of 1.78.

Analyst Ratings Changes

AVR has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Friday, May 29th. Wall Street Zen raised Anteris Technologies Global from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Barclays raised their target price on shares of Anteris Technologies Global from $17.00 to $18.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Insider Activity

In related news, major shareholder L1 Capital Pty Ltd sold 558,633 shares of the firm’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $8.20, for a total transaction of $4,580,790.60. Following the transaction, the insider owned 6,633,314 shares of the company’s stock, valued at $54,393,174.80. This trade represents a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 3,000,659 shares of company stock worth $25,174,702 over the last 90 days. Company insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

A number of hedge funds have recently added to or reduced their stakes in AVR. Price T Rowe Associates Inc. MD raised its stake in shares of Anteris Technologies Global by 78.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,875 shares of the company’s stock worth $115,000 after purchasing an additional 10,073 shares during the last quarter. Walleye Capital LLC purchased a new position in Anteris Technologies Global in the 4th quarter valued at $147,000. Wells Fargo & Company MN grew its position in Anteris Technologies Global by 78.1% in the 4th quarter. Wells Fargo & Company MN now owns 37,157 shares of the company’s stock valued at $185,000 after buying an additional 16,291 shares during the last quarter. Macquarie Group Ltd. increased its stake in Anteris Technologies Global by 12,369.6% in the 4th quarter. Macquarie Group Ltd. now owns 33,668 shares of the company’s stock valued at $168,000 after buying an additional 33,398 shares during the period. Finally, Deutsche Bank AG increased its stake in Anteris Technologies Global by 8.1% in the 4th quarter. Deutsche Bank AG now owns 28,865 shares of the company’s stock valued at $144,000 after buying an additional 2,171 shares during the period.

Trending Headlines about Anteris Technologies Global

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Anteris secured U.S. Medicare reimbursement eligibility under a Centers for Medicare & Medicaid Services national coverage policy for eligible procedures in its global pivotal PARADIGM Trial. The policy could improve trial participation and reduce reimbursement-related barriers at U.S. sites. Anteris Technologies Announces Results for the Second Quarter of 2026
• Positive Sentiment: Quarterly EPS improved from a loss of $0.58 in the year-ago period to a loss of $0.30, suggesting year-over-year progress despite the company remaining unprofitable.
• Neutral Sentiment: Analysts continue to project a full-year loss of approximately $1.14 per share, underscoring that AVR remains a development-stage medical-device company whose valuation depends heavily on clinical and regulatory execution.
• Negative Sentiment: Second-quarter results missed expectations: the company reported a $0.30 per-share loss versus the consensus loss estimate of $0.21, while revenue of $1.01 million fell short of the $1.50 million estimate. Anteris also reported an extremely negative net margin and return on equity. Anteris Technologies Announces Results for the Second Quarter of 2026
• Negative Sentiment: Major shareholder L1 Capital Pty Ltd sold 375,815 shares for about $3.50 million on August 11 and 251,844 shares for approximately $2.29 million on August 10. These transactions reduced its position by 7.25% and 4.63%, respectively, following additional recent sales. Repeated large-holder selling may weigh on investor sentiment and increase perceived supply overhang. SEC Filing

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.